Physician profile
Beth Earles
NPI 1225680127
$6,362.99
in general payments reported to CMS, 2019-2025
38 companies · $1,708 in 2025
The $1,708 reported for 2025 was more than what 93% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,281 · 2022: $1,364 · 2023: $721 · 2024: $1,289 · 2025: $1,708.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,718.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,718.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,007.27 | 2021-2025 | |
| Pfizer INC. | $781.78 | 2021-2025 | |
| Biogen, INC. | $520.96 | 2021-2025 | Tysabri, Vumerity, Spinraza |
| Lundbeck LLC | $483.93 | 2023-2025 | Vyepti, Rexulti |
| Eisai INC. | $344.78 | 2021-2025 | |
| Sk Life Science, INC. | $270.39 | 2021-2025 | |
| Neurocrine Biosciences, INC. | $244.02 | 2024-2025 | Ingrezza |
| Biohaven Pharmaceuticals, INC. | $222.86 | 2021 | |
| Alexion Pharmaceuticals, INC. | $215.75 | 2021-2025 | Ultomiris |
| Lilly USA, LLC | $201.83 | 2021-2024 | Reyvow, Emgality, Amyvid |
| Amgen INC. | $197.02 | 2021-2022 | |
| Ucb, INC. | $196.41 | 2021-2025 | Nayzilam, Zilbrysq |
| Biohaven Pharmaceutical Holding Company Ltd. | $189.05 | 2022 | |
| Genzyme Corporation | $185.27 | 2021-2023 | |
| Teva Pharmaceuticals USA, INC. | $182.86 | 2021-2025 | Austedo Xr, Austedo Xr |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beth Earles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.